New 3-D Imaging Tool To Detect Liver Diseases

by Shirley Johanna on  April 11, 2016 at 11:57 AM Medical Gadgets   - G J E 4
A novel 3-D imaging tool that can provide a highly accurate method to detect non-alcoholic fatty liver disease (NAFLD) has been developed by US research team led by an Indian-origin scientist.
New 3-D Imaging Tool To Detect Liver Diseases
New 3-D Imaging Tool To Detect Liver Diseases

The researchers at the University of California, San Diego, conducted a prospective study of 100 patients (56 percent women) with biopsy-proven NAFLD to assess the efficacy of two-dimensional magnetic resonance elastography (MRE) and a novel 3D version.

‘The new 3-D magnetic resonance elastography (MRE) tool creates images that measure the stiffness of the liver tissue, which is an indicator of fibrosis.’
They found that both MRE technologies were highly accurate for diagnosing advanced fibrosis, with 3D perhaps providing additional capabilities in some patients.

"3D MRE is probably the most accurate non-invasive method to detect advanced fibrosis," said Rohit Loomba, the study's first author and director of the NAFLD Research Centre at UC San Diego School of Medicine.

MRE is a specialized version of magnetic resonance imaging (MRI) that propagates mechanical shear waves in liver tissue. An algorithm creates images that quantitatively measure tissue stiffness -- an indicator of fibrosis.

The 2D version of MRE is already commercially available and easily implemented on basic MRI systems in clinics. Three-dimensional MRE is more technically demanding and not yet widely available.

The findings of the study, published recently in the American Journal of Gastroenterology, are encouraging because diagnosing NAFLD can be challenging.

Current non-invasive techniques, such as molecular biomarkers in blood, are not sufficiently accurate for routine clinical use. Ultrasound-based methods have high failure rates, particularly in obese patients.

"These findings suggest that MRE could be used to enroll patients with advanced fibrosis into screening programs for cirrhosis as well as enrollment into clinical trials aimed at reversing fibrosis in the setting of advanced fibrosis," Loomba said.

Source: IANS

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like